Resources
- sort by:
- Relevance
- Date
- Popularity
- Auxilium Inches Toward FDA Approval for Xiaflex
- Zacks.com submits: Auxilium Pharma AUXL is currently awaiting a decision from the U.S. Food and Drug Administration (FDA) on its key pipeline candidate, Xiaflex, which is under FDA review for the treatment of Dupuytren’s Contracture. In September, Auxilium received a major boost in the form of a favorable...
- External links 2009-10-14
- Auxilium Pharmaceuticals, Inc. Announces First Patients Dosed in XIAFLEX(TM) U.S. Pivotal Phase III Study
- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) today announced that the first patients have been dosed in the Company's second U.S. phase III pivotal trial and the Australian phase III study for XIAFLEXTM for the treatment of Dupuytren's contracture, a disabling and recurring condition in which the joints in the hand contract,...
- Research articles 2007-09-10
- Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p < 0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture
- Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) today announced positive top-line efficacy and safety results from the CORD I and CORD II phase III clinical trials for XIAFLEXTM clostridial collagenase for injection in the treatment of Dupuytren's contracture. Each of the CORD I and II trials successfully met the primary endpoint, a...
- Research articles 2008-06-03
- / CORRECTION - Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p < 0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture
- In the news release, "Auxilium Pharmaceuticals, Inc. Announces XIAFLEXTM Meets Primary Endpoint With Statistical Significance (p < 0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture," issued earlier today by Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), please be advised that Marketwire incorrectly replaced the "greater than or equal to"...
- Research articles 2008-06-03
- Auxilium Pharmaceuticals Inc. Q1 2008 Earnings Call Transcript
- Question-and-Answer SessionOperator Thank you. Operator Instructions. Your first question comes from the line of Salveen Kochnover, with Jefferies & Company. Please proceed. Salveen Kochnover - Jefferies & Company Sure. Hey, guys, good morning. Armando Anido Good morning, Salveen. Salveen Kochnover - Jefferies & Company Thank you for taking my...
- Earnings calls 2008-05-16
- Pfizer to Sell Penis-Straightening Drug
- Pfizer, the maker of Viagra, has struck a deal to sell Xiaflex, a drug that cures curvature of the penis ... There's just one drawback to Xiaflex -- it's administered by injection. by Jim Edwards
- Blog posts 2008-12-18
- Auxilium Pharmaceuticals, Inc. 3Q09 (Qtr End 9/30/09) Earnings Call Transcript
- Question-and-Answer SessionOperator Operator Instructions Your first question comes from the line of Marshall Urist with Morgan Stanley. Please proceed. Marshall Urist - Morgan Stanley Yeah, hi guys, good morning. Couple of things, first one just from your comments on the – on the Pfizer, Pfizer said in...
- Earnings calls 2009-10-28
- Auxilium Pharmaceuticals Q4 2007 Earnings Call Transcript
- Question-and-Answer SessionOperator Operator Instructions Your first question comes from the line of Salveen Kochnover of Jefferies. Please proceed. Salveen Kochnover - Jefferies Sure. Thanks for taking my questions. Armando, when you look at partnering XIAFLEX in the EU, are you looking at partnering it just for Dupuytren's or for...
- Earnings calls 2008-02-18
- The Pfizer-Wyeth Deal Worst-Case Scenario
- UPDATE: The deal is done! Pfizer will get Wyeth for $68 billion. See BNET's look at the deal here. Meanwhile here's the pre-deal analysis: Folks are freaking out right now on CafePharma -- sample quote on the Wyeth board: "You're Pfucked!" What will the new company be...
- Blog posts 2009-01-23
- Rexahn, Vivus Believe the World Needs 2 More ED Drugs
- Two companies are developing new erectile dysfunction drugs, even though there's already three on the market and one of those -- Pfizer's Viagra -- is set to go generic between 2011 and 2013. Rexahn is developing a compound called Zoraxel and Vivus is developing Avanafil. Rexahn is...
- Blog posts 2009-02-12
- Auxilium Pharmaceuticals Q4 2008 Earnings Call Transcript
- Question-and-Answer SessionOperator Operators Instructions. Your first question comes from the line of Marshall Urist from Morgan Stanley. Please proceed. Marshall Urist - Morgan Stanley Yeah, hey guys Good morning. First question is, can you just give us any kind of updates from the ... now that the safety database...
- Earnings calls 2009-02-18
- FDA Gives Pfizer's Penis-Straightening Drug Priority Review
- The FDA granted priority review status to a drug Pfizer is developing that will cure curvature of the penis. BNET readers first learned about Xiaflex -- and the rather less well publicized fact that it must be administered by injection into the organ itself -- back in December. by Jim...
- Blog posts 2009-04-30
- Pfizer's Penis-Straightening Drug May Cause "Swelling, Redness and Bruising"
- Xiaflex, the penis-straightening drug being developed by Auxilium for Pfizer, causes "a lot of different reactions such as swelling and redness and bruising" in some patients, according to Auxilium chief medical officer Anthony DelConte. by Jim Edwards
- Blog posts 2009-05-08
- << Previous
- page 1 of 1
- Next >>
